Stanford, CANCT05988463Now EnrollingIRB Ready

Idiopathic Pulmonary Fibrosis Clinical Trial in Stanford, CA

Access cutting-edge idiopathic pulmonary fibrosis treatment through this clinical trial at a research site in Stanford. Study-provided care at no cost to qualified participants.

Sponsored by Joseph C. Wu

Quick Self-Assessment

See if you qualify for this Stanford location

Preparing your pre-screening questions…

Expert Care in Stanford

Access idiopathic pulmonary fibrosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related idiopathic pulmonary fibrosis treatment provided free

Apply for This Stanford Location

Check if you qualify for this idiopathic pulmonary fibrosis clinical trial in Stanford, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Stanford

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Stanford site if eligible
  4. 4Begin participation

About This Idiopathic Pulmonary Fibrosis Study in Stanford

Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting in increasing shortness of breath, cough, and low oxygen levels as a result of lung tissue scarring . This will be a single-center randomized, double-blinded, placebo-controlled study of 20 weeks including up to 4 weeks for screening, followed by 12 weeks of oral artesunate treatment across 3 dose levels (dose escalation every 4 weeks), and 4 weeks of a washout (follow-up) period in participants with Idiopathic Pulmonary Fibrosis (IPF). The primary objective of the study is to evaluate the safety and tolerability of artesunate at 3 dose levels, and to select the dose(s) to carry forward into additional clinical testing. The secondary objective includes exploring the blood biomarkers present in participants with IPF at baseline and to investigate how those biomarkers change following artesunate treatment. The exploratory objectives include assessing the changes in the K-BILD and Leicester cough questionnaire scores and change in pulmonary function after artesunate administration.

Sponsor: Joseph C. Wu

Who Can Participate

Inclusion Criteria

Participants, aged 40 years or older.
Diagnosis of IPF based upon ATS/ERS/JRS/ALAT 2018 guidelines (55).
FVC percent of predicted ≥ 40%; historical FVC for entry in the study is permitted if within 3 months of screening.
Diffusing capacity of lung for carbon monoxide (DLco) (hemoglobin-adjusted) ≥ 30%; historical DLco for entry in the study is permitted if within 3 months of screening.
Participants currently receiving treatment for IPF with nintedanib or pirfenidone are allowed, provided these drugs have been given at a stable dose for at least 6 weeks before the Screening visit (stable dose is defined as the highest dose tolerated by the participant during ≥ 6 weeks).
Female participants of childbearing potential (i.e., ovulating, premenopausal, and not surgically sterile) and all male participants with sexual partners of childbearing potential must use highly effective methods of birth control during their participation in the study and for 60 days after the last administration of study drug. Highly effective methods of birth control are defined as those with 99% or greater efficacy.
Participants must agree to abstain from egg or sperm donation through 60 days, after administration of the last dose of study drug.
Able to read and sign a written informed consent form (ICF).

Exclusion Criteria

Receiving any nonapproved agent intended for treatment of fibrosis in IPF or Participation in other clinical trials.
Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, or sinusitis that can affect FVC measurement during screening.
Known acute IPF exacerbation or suspicion by the Investigator of such, within 3 months of screening.
The extent of emphysema is greater than the fibrotic changes on the most recent HRCT scan as determined by PI.
Any medical condition, not limited to cardiac, hepatic, renal disease or malignancy in recent months that will make the patients ineligible for the study, as deemed significant by PI.
Any of the following liver function test criteria above specified limits: total bilirubin \>2× the upper limit of normal (ULN); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3× ULN; alkaline phosphatase \> 2.5× ULN, pending PI's discretion.
Hemoglobin levels \< 10.0 g/dL.
Pregnant or lactating females.
Likely to have lung transplantation during the study (being on transplantation list is acceptable).
Currently receiving and expected to remain on treatment during the study with: amodiaquine, and efavirenz, nevirapine and ritonavir.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Stanford?

Yes, this clinical trial (NCT05988463) has an active research site in Stanford, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Idiopathic Pulmonary Fibrosis Treatment Options in Stanford, CA

If you're searching for idiopathic pulmonary fibrosis treatment options in Stanford, CA, this clinical trial (NCT05988463) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Stanford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced idiopathic pulmonary fibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all idiopathic pulmonary fibrosis clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Fibrosis Trials in Stanford, CA

See all pulmonary fibrosis clinical trials recruiting in Stanford — not just this study.

Browse Pulmonary Fibrosis Trials in Stanford →

Browse More Trials by Condition

Pulmonary Fibrosis TrialsInterstitial Cystitis TrialsFibromyalgia TrialsInterstitial Lung Disease TrialsAll Conditions →

Ready to Join in Stanford?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Stanford, CA